| P50 | author | Steven Rosenberg | Q2347448 |
| | Hui Xu | Q110142739 |
| P2093 | author name string | Paul F Robbins | |
| | Daniel Abate-Daga | |
| | Mahadev Rao | |
| | Shannon F Rosati | |
| | Richard A Morgan | |
| | Zhili Zheng | |
| | Steven A Feldman | |
| | Maria R Parkhurst | |
| | Mary A Black | |
| | Rachel E Beard | |
| | Young Hong | |
| | David A Schrump | |
| P2860 | cites work | NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target | Q36456502 |
| | Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy | Q36637039 |
| | Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions | Q36713758 |
| | Polycomb repressor complex-2 is a novel target for mesothelioma therapy | Q38330818 |
| | A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. | Q39621147 |
| | Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL | Q39655893 |
| | The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells | Q39716492 |
| | Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette | Q40003380 |
| | Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. | Q43551866 |
| | Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy | Q45858516 |
| | Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma. | Q46030251 |
| | Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. | Q51611724 |
| | Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. | Q53436850 |
| | Tumor-specific cytolysis by lymphocytes infiltrating human melanomas | Q69738303 |
| | A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening | Q24564781 |
| | Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy | Q24596055 |
| | Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen | Q24623215 |
| | Cancer/testis antigens: an expanding family of targets for cancer immunotherapy | Q28215652 |
| | Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 | Q29616128 |
| | Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes | Q32142930 |
| | Mixed T cell receptor dimers harbor potentially harmful neoreactivity | Q33934631 |
| | NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine | Q34182308 |
| | NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer | Q34325790 |
| | T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. | Q34621730 |
| | High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation | Q34657652 |
| | Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials | Q34678708 |
| | Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer | Q35050623 |
| | Neuroblastoma: developmental biology, cancer genomics and immunotherapy | Q35283020 |
| | NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery | Q35995828 |
| | Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma | Q36075245 |
| | Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion | Q36215613 |
| | Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability | Q36286127 |
| | Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells | Q36326582 |
| P433 | issue | 3 | |
| P304 | page(s) | 135-146 | |
| P577 | publication date | 2014-04-01 | |
| P1433 | published in | Journal of Immunotherapy | Q15763946 |
| P1476 | title | A novel murine T-cell receptor targeting NY-ESO-1. | |
| P478 | volume | 37 | |